December 15, 2015

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Kind Attn.: Ms. Usha Sharma, Dy. Manager, Surveillance & Supervision
Ms. Tina Jain, Associate Manager, Surveillance & Supervision

Dear Madam,


With reference to the above, we wish to clarify as under:

1. There is no new occurrence of which any notice has been received from Mylan in relation to US Food & Drug Administration.

2. On December 04, 2013, the Company and its wholly owned subsidiary Strides Pharma Asia Pte Limited ("Subsidiary") completed the sale to Mylan Laboratories Limited and Mylan Investments Inc. of Agila Specialties Private Limited and Agila Specialties Global Pte Limited respectively pursuant to sale and purchase agreements effective as of February 27, 2013 ("SPAs") for a total consideration of up to $1.75 billion.

3. As is common in such transactions, provisions were made in the agreements for potential claims by the purchaser, and as the Company has previously announced at the time the sale was completed, the Company/ Subsidiary deposited USD 100 Million into an escrow in respect of potential claims on warranties and indemnities and has also deposited a further USD 100 Million into an escrow in respect of potential claims under the SPAs in relation to certain regulatory concerns.

4. Claims can only be made by Mylan based on specific provisions contained in the agreements. The SPAs contemplate notifications of claims from the buyers by certain cut-off dates and actual claims thereafter by arbitration notices after completing certain procedures.

5. The Company has received notification of claims from Mylan within the first stipulated date in relation to certain provisions contained in the SPAs and in relation to certain regulatory concerns. The Company believes it can successfully defend these claims and is in the process of evaluating each claim notified by Mylan. In any event, the Company is confident that the ultimate claims will be within the escrowed amounts and will not result in unforeseen liabilities.
6. You would appreciate that while disclosing information to Stock Exchanges, the Company has to carefully weigh various factors, including the stage at which any such matter might be and that any premature disclosure could be misleading to the public and could cause confusion among investors.

7. As a responsible corporate that follows the highest standards of corporate governance, we are fully conscious of our disclosure obligations and can assure you that we will always act in consonance with these obligations and more.

We request you to take the above on record.

Thanking you,
For Strides Shasun Limited

[Signature]
Badree Komandur
CFO & Company Secretary